Mass tort litigation has resulted in significant recoveries for injury victims across the country. Below are notable settlements, verdicts, bankruptcy trust funds, and active multidistrict litigation (MDL) in the case types we handle. These figures demonstrate the scale of accountability being pursued against manufacturers, institutions, and other defendants.
Paraquat / Parkinson's
Syngenta, Chevron
A qualified settlement fund was approved in March 2026 to resolve approximately 6,500 claims in MDL 3004 (S.D. Illinois) alleging paraquat herbicide exposure caused Parkinson's disease. The formal agreement was signed in August 2025 with terms kept confidential, canceling the April 2026 trial schedule. Reported per-claim ranges depend on severity and exposure evidence.
Roundup Weedkiller
Bayer (Monsanto)
In February 2026, Bayer announced a proposed global class settlement to resolve current and future non-Hodgkin lymphoma claims over a 21-year period. Preliminary approval was granted in March 2026, with final approval expected mid-2026. Bayer has already paid approximately $11 billion across roughly 100,000 previously resolved cases since 2018, and the U.S. Supreme Court is expected to rule in June 2026 on a preemption question that could reshape remaining litigation.
See case details →
Mesothelioma & Asbestos
Asbestos Bankruptcy Trusts
More than 60 asbestos bankruptcy trusts remain active, with an estimated $30 billion in remaining capacity to compensate mesothelioma and asbestos-disease victims. Over $17 billion has been paid out historically. Individual trust fund payouts typically range from $300,000 to $400,000, while combined trust-plus-litigation recoveries for mesothelioma cases have historically averaged between $1 million and $2.4 million.
See case details →
Boy Scouts of America Trust
Scouting Settlement Trust (BSA)
The BSA reorganization plan resolving over 82,000 childhood sexual abuse claims was finalized on February 11, 2026, after the U.S. Supreme Court denied certiorari in January 2026. More than $316 million has been paid on 39,000+ approved claims as of early 2026, with the $1.65 billion escrow now released. The trust aims to resolve all remaining claims by the end of 2026.
See case details →
Juvenile Detention & Foster Care Abuse
Los Angeles County
In April 2025, the L.A. County Board of Supervisors approved a $4 billion settlement covering more than 6,800 sexual abuse claims from former residents of county juvenile halls and the foster care system. An additional $828 million for roughly 400 more claims was announced in October 2025, bringing the total to approximately $4.8 billion. California's AB 218 revival window enabled claims dating back more than 60 years, making this the largest institutional child abuse settlement in U.S. history.
See case details →
Zantac / Ranitidine
GlaxoSmithKline, Sanofi
GlaxoSmithKline agreed in 2025 to pay up to $2.2 billion to resolve approximately 80,000 cases alleging ranitidine degraded into the carcinogen NDMA. Sanofi also resolved most of its inventory in September 2025. Delaware Supreme Court and trial court rulings in 2025-2026 excluded key causation testimony, effectively closing many remaining claims.
PFAS Industrial Contamination
DuPont, Chemours, Corteva
DuPont, Chemours, and Corteva agreed to a $1.185 billion nationwide public-water settlement in 2023. In August 2025, the same companies announced a separate $875 million settlement with the State of New Jersey to resolve all environmental and PFAS claims at Chambers Works, Parlin, Pompton Lakes, and Repauno. The New Jersey payments span 25 years beginning no earlier than January 2026.
See case details →
PFAS Water Contamination
3M Company
3M agreed in 2023 to pay $10.3 billion (up to $12.5 billion gross) over 13 years to resolve nationwide claims from U.S. public water systems contaminated with PFAS 'forever chemicals.' A separate $450 million statewide PFAS settlement with New Jersey was announced in May 2025, with payments running 2026-2034. First payments to water utilities began in summer 2025.
See case details →
Archdiocese of Los Angeles
Roman Catholic Archdiocese of Los Angeles
In October 2024, the Archdiocese announced a settlement covering 1,353 clergy sexual abuse claims filed under California's AB 218 revival window. Combined with a 2007 payout of $740 million, the Archdiocese's lifetime clergy abuse payout now exceeds $1.5 billion, the largest single-diocese payout in U.S. history. The settlement is being funded through reserves, asset sales, and loans rather than bankruptcy.
See case details →
Hernia Mesh
C.R. Bard / Becton Dickinson
A global resolution covering approximately 38,000 hernia mesh personal injury cases was announced in October 2024 in MDL 2846 (S.D. Ohio). Disbursements began in 2025 and are scheduled over several years. The settlement followed bellwether verdicts and pressure from tens of thousands of consolidated polypropylene mesh claims.
Philips CPAP & BiPAP Recall
Philips Respironics
Following the 2021 recall of millions of sleep and respiratory devices over degrading polyurethane foam, Philips agreed in April 2024 to a $1.1 billion personal injury settlement (including $25 million in medical monitoring). A separate $479 million economic-loss class settlement reached preliminary approval in 2023, with payments beginning in 2024. Cancer injury claims remain pending within the MDL.
Baby Formula NEC
Abbott (Similac), Mead Johnson (Enfamil)
Federal MDL 3026 (N.D. Ill.) consolidates claims that cow's milk-based premature infant formulas cause necrotizing enterocolitis (NEC). Notable verdicts include $495 million against Abbott (St. Louis, 2024), $60 million against Mead Johnson (Illinois, 2024), and a $53 million verdict for four mothers against Abbott in April 2026. A Cochrane Review found formula-fed premature infants face a 3-10x higher NEC risk than those receiving human milk.
See case details →
Hair Relaxer
L'Oreal, Revlon
Federal MDL 3060 (N.D. Ill.) now holds an estimated 10,000 to 15,000 cases alleging chemical hair straighteners caused uterine cancer, ovarian cancer, and fibroids. A landmark 2022 NIH-funded study linked frequent use to a 2.5x higher uterine cancer risk. Science Day was held in January 2026, with the final bellwether pool selected in March 2026; the first bellwether trials are now expected in 2027.
See case details →
Social Media Youth
Meta, TikTok, Snap, YouTube/Google
The first bellwether trial (KGM v. Meta/YouTube, California JCCP 5255) returned a $3 million compensatory verdict in February 2026, assigning 70% liability to Meta and 30% to Google, with punitive damages to follow. TikTok and Snap both settled with the plaintiff on the eve of trial. MDL 3047 (N.D. Cal.) now holds more than 2,400 cases alleging that addictive design features caused adolescent anxiety, depression, and suicidality.
See case details →
Rideshare Assault & Injury
Uber, Lyft
The first bellwether trial in MDL 3084 (Uber, N.D. Cal.) ended in February 2026 with an $8.5 million verdict in favor of plaintiff Jaylynn Dean, with the jury finding the driver acted as Uber's apparent agent. A separate Lyft MDL was approved by the JPML on February 6, 2026. More than 3,300 plaintiffs are now consolidated against Uber across 30 states. No global settlement has been reached.
See case details →
Talcum Powder
Johnson & Johnson
Johnson & Johnson's third bankruptcy attempt through Red River Talc was dismissed in March 2025, collapsing the previously proposed $8.9 billion global settlement. More than 67,000 cases remain pending in the federal MDL as of April 2026. Individual trials continue producing major verdicts, including a $1.5 billion Maryland verdict in December 2025, the largest talc verdict on record.
See case details →
Depo-Provera Meningioma
Pfizer
Cases were consolidated into MDL 3140 (N.D. Fla., Judge M. Casey Rodgers) in February 2025. Approximately 3,490 cases are pending as of April 2026, with an estimated 10,000 additional unfiled claims. The FDA approved a meningioma warning label change in December 2025, and Daubert/general causation hearings are set for June 2026, with the first pilot trials scheduled for December 2026.
See case details →
Ozempic / GLP-1 Drugs
Novo Nordisk, Eli Lilly
Two related federal MDLs before Judge Marston (E.D. Pa.) consolidate claims against Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound). MDL 3094 (approximately 3,550 cases) covers gastroparesis, intestinal obstruction, and ileus. MDL 3176, established in December 2025, covers GLP-1-linked vision loss (NAION). A severe-gastroparesis caution was added to the Ozempic label in January 2025.
See case details →
Baby Food Heavy Metals
Walmart, Beech-Nut, Gerber, Hain
MDL 3101 (N.D. Cal.) consolidates claims that toxic heavy metals in infant and toddler food caused autism and ADHD diagnoses. A 2021 Congressional report found 95% of tested baby foods contained arsenic, lead, cadmium, or mercury. More than 400 cases are pending as of April 2026 following an April 2025 ruling that allowed defective-manufacturing, negligence, and failure-to-warn claims to proceed. A key causation hearing was held in December 2025.
See case details →
AFFF Firefighting Foam
3M, DuPont, Tyco
Approximately 15,000 personal injury cases are pending in MDL 2873 (D.S.C.) as of April 2026, alleging AFFF foam containing PFAS chemicals caused kidney cancer, testicular cancer, and other conditions. The October 2025 bellwether trial was vacated, and the court is building a second bellwether pool of 28 drinking-water-exposure claims. A personal injury settlement is anticipated in 2026-2027. 3M's $10.3 billion PFAS water settlement does not cover individual injury claims.
See case details →
Suboxone Tooth Decay
Indivior
MDL 3092 (N.D. Ohio) consolidates approximately 20,000 claims that Suboxone sublingual film's acidic formulation caused severe tooth decay, tooth loss, and enamel erosion. Plaintiffs allege Indivior failed to warn until updating its label in 2022. Bellwether trials are expected in 2026.
See case details →
Exactech Implants
Exactech, Inc.
MDL 3044 (E.D.N.Y.) consolidates more than 1,500 cases arising from Exactech's recall of polyethylene inserts in knee, hip, and ankle replacements due to defective packaging that caused premature wear. Exactech filed for bankruptcy in 2025, effectively freezing MDL proceedings while an asset transfer to lenders and a claimant trust structure are negotiated.
See case details →
Prior results do not guarantee a similar outcome. These figures reflect industry-wide settlements, verdicts, and trust fund totals, not results obtained by UnitedClaimsBureau. Individual case outcomes depend on the specific facts and legal circumstances involved. Settlement amounts referenced are aggregate totals across all claimants, not individual payouts. Figures current as of April 2026.